AFT Pharmaceuticals posts record profit on global expansion and R&D push

AFT Pharmaceuticals Ltd. ( (NZ:AFT) ) has shared an update.

AFT Pharmaceuticals reported a 22% rise in full-year operating revenue to $254.7 million and a record operating profit of $24.4 million, underpinned by double-digit sales growth across all territories and strong performance in Australia and New Zealand. Net profit after tax climbed 24% to $14.1 million, while a higher dividend signalled management’s confidence, even as net debt rose to $38.6 million due to expanded working capital and product acquisitions, particularly in South Africa.

International and Asian markets delivered sharp gains, with product sales and royalties up 66% and 41% respectively, as AFT scaled hubs in the U.K., Europe, North America and South Africa and broadened distribution of its Maxigesic/Combogesic range, including launches of Combogesic IV in Canada and U.K. hospitals. The company increased R&D investment to $18 million across pain, dermatology, eyecare and injectables, advancing late-stage projects such as an intravenous iron therapy, fridge‑free injectables and paediatric Maxigesic studies, and is targeting revenue above $300 million and operating profit of $28–$32 million by FY27 as operating leverage improves.

More about AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals is New Zealand’s largest locally based pharmaceuticals company, focused on over-the-counter brands, prescription medicines and proprietary products such as its Maxigesic/Combogesic pain relief range. The company is expanding beyond its core Australasian base into the U.K., Europe, North America, Asia and South Africa, building international hubs and out-licensing its R&D-driven portfolio to address unmet clinical needs.

Average Trading Volume: 12,589

Technical Sentiment Signal: Buy

Current Market Cap: N$364.9M

See more insights into AFT stock on TipRanks’ Stock Analysis page.